Thus, through inhibiting the invasion and metastasis of tumor cells and concomitantly eliciting endogenous antitumor immune responses, Axl-targeting therapeutics, alone or optimal combination with other conventional treatments, may overcome the therapeutic resistance and broaden the scope of cancer patients benefited from ICB-based immunotherapy. This evidence concerns the gene AXL and cancer.